Exelixis (EXEL) Tops Q4 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Exelixis (EXEL) PT Raised to $33 at Needham & Company
February 13, 2019 10:52 AM ESTNeedham & Company analyst Chad Messer raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $30.00) while maintaining a Buy rating.
Messer commented, "Exelixis reported $176M in Cabo sales in 4Q:18, an 8% increase q/q. FY18 Cabo sales were $619M, a 44% increase... More
Exelixis (EXEL) PT Raised to $33 at Guggenheim Following 4Q
February 13, 2019 10:01 AM ESTGuggenheim analyst Michael Schmidt raised the price target on Exelixis (NASDAQ: EXEL) to $33.00 (from $31.00) while maintaining a Buy rating following the company's 4Q earnings report. EXEL reported 4Q18 revenue of $229M, 22% above Street consensus of $188M. Non-GAAP diluted EPS was 0.37, driven mostly by a... More
Exelixis (EXEL) PT Lowered to $31 at Oppenheimer
February 13, 2019 7:58 AM ESTOppenheimer analyst Silvan Tuerkcan lowered the price target on Exelixis (NASDAQ: EXEL) to $31.00 (from $40.00) while maintaining a Outperform rating.
The analyst commented, "EXEL reported 4Q $176.2M revenue beating $170.0M consensus driven by Cabometyx sales of $171.6M vs $166M consensus. Cabometyx sales grew... More
